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Abstract: Nucleolar organizer regions (NORs)
are chromosomal segments in which
ribosomal RNA is encoded. The AgNOR
technique, which reveals these regions, has
rarely been used in diagnosis and preceding
the prognosis of pituitary adenoma. The
purpose of this study was to evaluate the
correlation of hormonal profile with the
AgNOR counts, and the correlation of
recurrence with the AgNOR counts and to
determine the concordance between the
evaluations of two different observers. This
study included 33 patients w›th pituitary
adenoma. The slides were stained with
hematoxylin and eosin, silver colloid method
for NORs and immunohistochemistry for the
hormone expressions.
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Introduction
Pituitary adenomas constitute 10% of all intracranial
tumors. Although these are benign lesions, their growth
rate is variable, and the recurrence risk is about 10-35%.
They may be hormonally inactive or synthesize one or
more hormones, i.e., FSH, LH, TSH, GH, ACTH and PRL
(1).
NOR related proteins are acidic non-histone proteins
stained by silver (2-4). Although their real biological
functions are disputed, the AgNOR result for each cell is
considered as a marker of cellular activity (2, 5). Today,
AgNOR staining has diagnostic and prognostic value in
hyperplastic events and malignancies such as lymphomas,
breast carcinomas and hepatomas, although there are
some opposing opinions (2, 3, 6, 7). Some researchers
also consider it to be a marker showing the
differentiation grade of malignant neoplasms (3).
Three main configurations of AgNOR are identified (4):
1. Round argyrophylic structures indicating the small
nucleolus of stable cells
2. AgNOR groups in a matrix indicating the nucleolus

Consistency was strong among the two
pathologists (for hormonal profiling, the
kappa test was used and p<0. 001; for
AgNOR count, the intraclass correlation
coefficient was 0. 83). There was no
significant relationship between mean AgNOR
counts and hormone expression (p>0. 05). In
addition, we found no difference between
recurrent patients and non-recurrent ones in
terms of mean AgNOR numbers (p>0. 05).
However, in recurrent patients, nucleolar
silver staining was more frequently detected
as clusters of AgNORs.

Key Words: Pituitary adenoma, AgNOR,
immunohistochemistry, recurrence.

3. Small point-like structures in nucleoplasm
In this study, we investigated the correlation between
hormone profile and AgNOR values in addition to the
correlation between recurrence and AgNOR values,
considering the conformity among the observers.

Materials and Methods
Thirty-three pituitary adenoma patients, diagnosed in
the pathology department of SSK Ankara Education
Hospital between 1984 and 1998, were examined. Five
cases were recurrent and the average follow–up period
was 3. 4 years (41 months). In 30 patients, adenomas
were intracapsular and were almost totally excised, but in
three patients, partial excision was carried out. Two cases
recurred because of the residual tumor. Only five cases
recurred in the totally excised group.
AgNOR Staining
Sections of 3-4 micron thickness were cut from the
routinely processed paraffin blocks. These were dewaxed
in xylene and then rehydrated through ethanols to
distilled, deionized water. The AgNOR solution was
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prepared by dissolving gelatine in 1g/dl aqueous formic
acid at a concentration of 2g/dl. This solution was mixed
(1: 2 volumes) with 50 g/dl aqueous silver nitrate
solution. The sections were washed off with deionized
water after keeping them in darkness for 30 min at room
temperature. They were closed after dehydration.
Counting procedure
AgNOR stained sections were examined by two
pathologists using a x1000 oil immersion objective. For
each case, all dark points indicating the AgNOR proteins
in the nucleus were counted in 100 tumor cells. Stromal
cells and inflammatory cells were excluded. Dark points
were counted one by one when it was possible to see the
inside of the nucleolus, but counted as one when the
interior was not clear. Then the mean AgNOR value for
each case was calculated.
In addition, for hormone profiling the sections taken
from all patients were stained with FSH, TSH, PRL, LH,
GH and ACTH immunohistochemically by using the
streptavidin-biotin technique. Each case was stained for
all hormones. These slides were also examined by two
pathologists, under a light microscope. In order to
determine the differences between the two observers,
the kappa test was used for hormone profiling and
intraclass correlation coefficient test for mean AgNOR
values. The Mann-Whitney test was used to determine the
correlation between hormone profiles and AgNOR values.
T test was used to compare the recurrent cases with the
others.

Results
The ages of the patients ranged from 16 to 69.
Eighteen cases were women and 15 were men. Among
the recurrent cases, two were in women and three in
men, with ages ranging from 30 to 62. In both groups,
there were complaints of headache, decreased vision and
enlargements of the hands and feet. In female patients,
galactorrhea and amenorrhea were additional complaints.
Immunohistochemically detected hormone profiles in
comparison with the clinical findings are shown in Table
1. In 27 cases, one hormone was synthesized, whereas in
six cases, the number of hormones synthesized was more
than
one.
It
was
observed
that
the
immunohistochemically detected hormone profile had a
correlation with clinical findings.
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Table 1.

Hormonal profiles of the cases immunohistochemically
(IHC) and clinically. Recurrent cases are marked with an
asterisk.

Case

1st observer(IHC)

2nd observer(IHC)

Clinically

1
2
3
*4
5
6
7
8
9
10
11
12
*13
14
15
16
*17
*18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
*33

Hormone -Hormone -FSH, GH
Hormone -Hormone -PRL
Hormone -PRL
GH
PRL
PRL
PRL
PRL, GH
PRL
GH
FSH
Hormone -Hormone -GH
Hormone -FSH, GH
ACTH
PRL, GH
Hormone -Hormone -Hormone-Hormone -PRL
GH
PRL, LH, GH
Hormone -GH
PRL

Hormone -Hormone -Hormone -Hormone -Hormone -PRL, GH
Hormone -PRL
GH
PRL
PRL
PRL
PRL, GH
PRL
GH
FSH
Hormone -Hormone -Hormone -Hormone -FSH, GH
ACTH
PRL, GH
Hormone -Hormone -Hormone -Hormone -Hormone -GH
GH, PRL
Hormone-GH
PRL

Hormone
Hormone
FSH, GH
Hormone
Hormone
PRL, GH
Hormone
PRL
GH
Hormone
PRL
PRL
PRL
PRL
GH
FSH
Hormone
GH
GH
PRL
Hormone
ACTH
PRL
Hormone
Hormone
PRL
Hormone
PRL
GH
PRL, LH
Hormone
GH
PRL

------

--

--

--

----

--

AgNORs were observed as dark points of variable size
in the nucleus and in some cases in the nucleolus (Figures
1, 2).
The mean AgNOR values are shown in Table 2. The
mean AgNOR values according to the hormones were as
follows: hormone (-): 2. 06, GH: 1. 85, FSH: 1. 79, PRL:
1. 96, ACTH: 2. 63, PRL and GH mixed: 1. 63, FSH and
GH mixed: 1. 15, LH, GH and PRL mixed: 1. 83.
AgNOR values according to the hormones are shown
in Figure 3. There was no correlation between hormones
and the AgNOR values (p>0. 05). For the five recurrent
cases, the mean AgNOR value was 1. 66, and it was 2. 02
for the others. No significant difference between these
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Table 2.

Mean AgNOR values. Recurrent cases are marked with an
asterisk
1st observer

Case

two groups was observed. Mean AgNOR values for
recurrent and nonrecurrent cases are shown in Figure 4.
Interior of the nucleolus was counted as one in five
recurrent (100%) and 12 non-recurrent (50%) cases.
There is strong conformity between the two observers in
evaluating the immunohistochemical staining and the
AgNOR values (p<0. 01). Immunohistochemical GH
positivity in the tumor cells is seen in Figure 5.

46
57
30
69
00
42
10
88
01
65
80
62
51
00
23
79
37
49
15
17
00
46
79
15
64
82
32
35
75
83
76
87
10

16

4.0 —
3.5 —
3.0 —
2.5 —
2.0 —
1.5 —

Figure 3.

1

—

7
PRL

—

.5
N = 13
6
Hormone (-)
GH

—

15

1.0 —
—

NOR proteins are the r DNA areas. They are located in
the nucleus and contain the gene for ribozomal RNA. Five
chromosomes contain NOR. NOR-related argyrophilic
molecules (RNA polymerase 1, C23pr, a molecule like
C23 but smaller, another molecule with a molecular mass
of 80 kDa) can be demonstrated immunologically (8).

3.
2.
1.
1.
1.
1.
3.
1.
2.
2.
1.
1.
1.
1.
1.
1.
1.
1.
4.
2.
1.
2.
1.
1.
1.
1.
2.
1.
1.
1.
1.
1.
2.

4.5 —

AgNOR

Discussion

11
58
32
69
06
44
12
18
06
87
82
75
62
00
28
80
57
50
17
18
00
81
02
90
56
91
60
35
85
83
99
87
10

—

A recurrent pituitary adenoma. AgNOR clusters in nuclei
are shown in black (AgNOR x1000).

—

Figure 2.

—

AgNOR spots in nuclei in a case of pituitary adenoma
(AgNOR x1000).

3.
2.
1.
1.
1.
1.
3.
2.
2.
2.
1.
3.
1.
1.
1.
1.
1.
1.
4.
2.
1.
2.
2.
1.
2.
1.
2.
1.
1.
1.
1.
1.
2.

—

Figure 1.

1
2
3
*4
5
6
7
8
9
10
11
12
*13
14
15
16
*17
*18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
*33

2nd observer

1
2
3
1
ACTH
PRL, GH
FSH
FSH, GH PRL, GH, LH

Graph of the mean AgNOR values for hormones.
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4.5

—

4.0

—

3.5

—

3.0

—

2.5

—

2.0

—

1.5

—

1.0

—

and the distribution pattern of AgNOR, in addition to the
AgNOR values, were meaningful (13, 14).

Figure 4.

28
Non - Recurrent

—

.0
N=

33

—

AgNOR

19

5
Recurrent

Graph of the mean AgNOR values of recurrent and nonrecurrent cases.

In the present study, the AgNOR counting was done
by evaluating the spots in the nucleus and nucleolus (2).
The spots in the nucleolus were counted as one since the
intranucleolar area was not clear. No significant
difference was detected between the AgNOR values of
recurrent and nonrecurrent cases. NOR regions in the
nucleolus were not clear in all recurrent and 50% of
nonrecurrent cases. For this reason, we think that cases
with nucleolar AgNOR staining as clusters have a higher
probability of recurrence. The importance of clusters and
spots in counting varies (4, 15, 16). Clusters indicate
nucleolar structures and they are formed when ribosomal
genes are active and the interphase is long enough (17,
18). Grotto et al. observed widespread multiple points in
rapidly proliferating cells. Clusters are more common in
undifferentiated cells and NORs not only show the
activation level but also the differentiation degree. As the
cells become differentiated, AgNOR staining becomes
point-like.
The number of nuclei to be counted for obtaining
AgNOR values is also a subject for discussion. While Orrell
et al. preferred 30 nuclei, Aoki et al. preferred 200 (2).
In the present study, we counted 100 nuclei.

Figure 5.

Pituitary adenoma. (+) immunoreactivity for growth
hormone in tumor cells (immunoperoxidase x 400).

The AgNOR technique is a practical and simple
technique. It is used as a marker for tumor cell
proliferation by pathologists. AgNOR values are
correlated with Ki-67 immunoreaction and DNA flow
cytometry (4, 9, 10).
There are two different methods for counting
AgNORs. In the first method, the AgNOR clusters are
considered to be a single structure (2). In the second, if it
is possible to see inside, it is counted one by one, and if it
is not possible it is again counted as a single structure.
Orrell et al. proposed that it was necessary to count
intranucleolar spots as well as the extranucleolar spots
(11). However, Howatt et al. Stated that counting the
intranucleolar spots led to intraobserver variability (12).
Other scientists did not find either technique to be
superior (13). As a result of these differences in the
counting techniques, it is expressed that the morphology
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Higher AgNOR values are observed in malignant cells
than in benign and non-neoplastic cells (7). Therefore
they have been studied in many different tumor types (2,
3, 6). Crocker and Nar used the AgNOR technique to
differentiate high and low grade non-Hodgkin
lymphomas (19). Crocker and Skilbeck applied this
method to nevus and malignant melanoma cases, whereas
Egan et al. used it in small round cell carcinomas of
childhood (8, 20-22). In a study by Elagöz et al., the
value of the AgNOR method alone in the diagnosis of
melanotic lesions is discussed. It was concluded that the
value of the AgNOR method alone is limited and other
techniques such as visual analysis are required (13).
In our study, mean AgNOR values for pituitary
adenomas were between 1 and 4.17. The highest values
were observed in hormonally inactive cases and no
significant relation between AgNOR values and hormones
was demonstrated. In recurrent cases, the AgNOR values
were observed at low levels. Although hormone (-) cases
have the highest AgNOR values, in three recurrent cases
no hormone expression was observed.
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The differences between the values obtained by each
observer is about 10-12% in the literature (13, 23, 24).
The reasons for these differences are the
nonstandardized method, fixation conditions, thickness of
sections, time for staining, heterogeneity of tumoral
tissues, evaluation of different areas by each observer,
and including the lymphocytes, histiocytes and endothelial
cells while counting (13, 15, 25, 26). These problems are
less significant in cytological preparations, since all cells
are smeared on slides. When the counting technique is
standardized, the conformity between observers
increases. In our study this conformity was strong
(intraclass correlation coefficient test: 0. 83).
Ten to thirty-five percent of pitutary adenomas recur
in 4-20 years (1). Of our cases, 15. 1% are recurrent.
Mindermann et al. found 6. 4% recurrent cases in a study
composed of 65 pituitary adenoma cases (27). In a study
by Hsu et al. the ages of patients with recurrent pituitary
adenomas were between 23 and 74. Our recurrent cases
occurred in patients between 30 and 62 years old.
In two cases in our study, no hormone or related
clinical findings were detected, while there was
immunohistochemical positivity. It is known that 30-40%
of pituitary adenomas are nonsecretory, although most of
them stain positive for hormones immunohistochemically

(28). In another two cases, although there was a
hormonal increase in the blood and corresponding clinical
findings, no immunohistochemical positivity was detected
in the tissue. This can be explained by the mechanism of
stalk inhibition in the pituitary gland (29). Two of the five
recurrent cases were hormone (-) both clinically and
immunohistochemically. One of the remaining cases was
PRL (+) both clinically and immunohistochemically.
Another one was hormone (-) immunohistochemically and
GH (+) clinically. While the last case was PRL and GH (+)
immunohistochemically, it was only PRL (+) clinically.
Carboni et al. found no prominent relation between
hormone expression in pituitary adenomas and the
recurrence and the proliferation index (30).
In conclusion, in our opinion, although AgNOR values,
morphology and distribution properties are used for
many organs, their value is limited in pituitary adenomas
and they should be used with other proliferation markers.
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